Analyst Price Target is $18.50
▲ +117.65% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for ARS Pharmaceuticals in the last 3 months. The average price target is $18.50, with a high forecast of $19.00 and a low forecast of $18.00. The average price target represents a 117.65% upside from the last price of $8.50.
Current Consensus is
Buy
The current consensus among 4 polled investment analysts is to buy stock in ARS Pharmaceuticals. This Buy consensus rating has held steady for over two years.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Read More